The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal Cancer
Abstract
Purpose: To determine the maximum-tolerated dose (MTD) of concurrent systemic oxaliplatin (Oxal) combinations plus hepatic arterial infusion (HAI) in patients with unresectable hepatic metastases from colorectal cancer. Patients and Methods: Thirty-six patients (89% previously treated) with unresectable liver metastases were treated with concurrent HAI and systemic Oxal plus irinotecan (CPT-11; group A) or Oxal, fluorouracil (FU), and leucovorin (LV; group B). Systemic chemotherapy was administered every 2 weeks concurrent with 2 weeks of HAI floxuridine (FUDR) and dexamethasone (Dex) every 28 days. Results: The MTD for patients in group A was Oxal 100 mg/m 2, CPT-11 150 mg/m 2, and FUDR 0.12 mg/kg × 30 mL divided by pump flow rate. The MTD for group B was Oxal 100 mg/m 2, LV 400 mg/m 2, and FU 1,400 mg/m 2 by continuous infusion over 48 hours, with the same FUDR dose as in group A. Grade 3 or 4 toxicities in groups A and B included diarrhea (24% and 20%), neutropenia (10% and 7%), neurotoxicity (24% and 20%), and bilirubin more than 3 mg/mL (5% and 7%, respectively). The complete and partial response rate totaled 90% for group A and 87% for group B. Median survival time was 36 and 22 months for groups A and B, respectively. Seven patients in group A were ultimately able to undergo liver resection. Conclusion: Combination therapy with HAI FUDR and Dex plus systemic Oxal combinations may be safely administered to patients with colorectal cancer. The high response rate (88%) and the possibility of conversion to resectability, despite disease progression on prior systemic regimens, suggest that these combinations should be evaluated in larger studies as first- or second-line therapy in patients with hepatic metastases from colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Meta-Analysis Group In Cancer (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.5.252 · Cited by 441
Cited by
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
Van Cutsem, E., Nordlinger, B., Adam, R., Köhne, C.-H., Pozzo, C., Poston, G., Ychou, M., & Rougier, P. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.04.012 · Cited by 587
Kemeny, N. E., Niedzwiecki, D., Hollis, D. R., Lenz, H.-J., Warren, R. S., Naughton, M. J., Weeks, J. C., Sigurdson, E. R., Herndon, J. E., Zhang, C., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8166 · Cited by 417
Self-citationKemeny, N. E., Melendez, F. D. H., Capanu, M., Paty, P. B., Fong, Y., Schwartz, L. H., Jarnagin, W. R., Patel, D., & D'Angelica, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1301 · Cited by 313
Self-citationStewart, C. L., Warner, S., Ito, K., Raoof, M., Wu, G. X., Kessler, J., Kim, J. Y., & Fong, Y. (2018) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2018.08.004 · Cited by 287
Self-citation
Metadata
- Authors
- Kemeny, N., Jarnagin, W., Paty, P., Gönen, M., Schwartz, L., Morse, M., Leonard, G., D’Angelica, M., DeMatteo, R., Blumgart, L., & Fong, Y.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-08-01
- Volume
- 23
- Issue
- 22
- Pages
- 4888-4896
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2154009817
- Cited by
- 223
- References
- 2
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal Cancer. https://app.cochat.ai/papers/10.1200/jco.2005.07.100
- The paper
- Kemeny, N., Jarnagin, W., Paty, P., Gönen, M., Schwartz, L., Morse, M., Leonard, G., D’Angelica, M., DeMatteo, R., Blumgart, L., & Fong, Y. (2005). Phase I Trial of Systemic Oxaliplatin Combination Chemotherapy With Hepatic Arterial Infusion in Patients With Unresectable Liver Metastases From Colorectal Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.07.100
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.